Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

Key Points

• To evaluate the effectiveness and safety of afamelanotide in patients with erythropoietic protoporphyria (EPP).
• Analysis of real-world data from an Austrian cohort of EPP patients.
• Assessment of quality of life and light tolerance before and after afamelanotide treatment.
• Afamelanotide was effective in improving the quality of life of EPP patients.
• Patients showed increased light tolerance after receiving afamelanotide treatment.

Abstract